ライフサイエンスコーパス: passive immunotherapy

1 provide a new insight for the development of passive immunotherapy.

2 r therapeutic intervention through augmented passive immunotherapy.

3 east cancer, a number of concerns exist with passive immunotherapy.

4 sition to evaluate the effects of anti-Abeta passive immunotherapy.

5 roles against malignancy in both active and passive immunotherapy.

6 nous IgG or monoclonal antibody cocktail for passive immunotherapy.

7 ent with conventional active vaccination and passive immunotherapy.

8 their levels, such as secretase inhibitors, passive immunotherapy against Abeta and mGluR5 antagonis

9 K should be further explored as a target for passive immunotherapy against complicated S. aureus infe

10 Passive immunotherapy against HIV-1 will most likely req

11 NA represents a viable delivery platform for passive immunotherapy against HIV-1 with expansion to a

12 e is an urgent need for the development of a passive immunotherapy against the category B select agen

13 monoclonals can be potential candidates for passive immunotherapy and for guiding immunogen design.

14 ding mutations in the hE16 epitope to resist passive immunotherapy and for the selection of neutraliz

15 More than ten new approaches to active and passive immunotherapy are under investigation in clinica

16 These findings have implications for passive immunotherapy as an approach toward controlling

17 The results indicate that passive immunotherapy can accelerate elimination of HIV-

18 These results suggest that early passive immunotherapy can eliminate early viral foci and

19 rulence factor for R. oryzae, and anti-Ftr1p passive immunotherapy deserves further evaluation as a s

20 Our results show that passive immunotherapy during acute SHIV infection differ

21 e greatest promise for generating active and passive immunotherapies for treating overdose or addicti

22 provide a safer therapeutic alternative for passive immunotherapy for AD.

23 t into the mechanism of action of a specific passive immunotherapy for AD.

24 orum quenching vaccines for use in active or passive immunotherapy for prevention or treatment of S.

25 Here we report for the first time on passive immunotherapy for Tau in two well established tr

26 hese data cast further doubt on the value of passive immunotherapy for the treatment of EBOV infectio

27 Passive immunotherapy for treatment or prophylaxis of HI

28 complex class I and II molecules, active and passive immunotherapy has moved to center stage once aga

29 can be used to predict the effectiveness of passive immunotherapies in mouse models.

30 Moreover, the success of passive immunotherapy in small-animal models suggests th

31 fection is frequently cited as evidence that passive immunotherapy is a viable treatment option.

32 Passive immunotherapy is an approved method used to prot

33 Thus, passive immunotherapy is effective at preventing the bui

34 However, such passive immunotherapy is unlikely to maintain memory T c

35 mmune plasma demonstrates the feasibility of passive immunotherapy, it is limited in quantity, variab

36 lso show that targeting these oligomers with passive immunotherapy leads to some improvement in motor

37 rus infection and raise the possibility that passive immunotherapy may be useful in HCPS.

38 phorylation and then neuritic dystrophy, but passive immunotherapy mitigates this.

39 study, an ovine antibody-based platform for passive immunotherapy of C. difficile infection is descr

40 17-1A and GA733, has been a useful target in passive immunotherapy of CRC patients with mAb and in ac

41 basophil activation and might be useful for passive immunotherapy of grass pollen allergy.

42 l antibodies (MAbs) are being considered for passive immunotherapy of HIV-1 infection.

43 e developed against Shiga toxin 1 (Stx1) for passive immunotherapy of HUS.

44 y have important implications for active and passive immunotherapy of prostate and other cancers.

45 ssociated micro-hemorrhages, i.c.v.-targeted passive immunotherapy offers a promising therapeutic app

46 imaging was employed to study the effects of passive immunotherapies on lethality and viral dissemina

47 Passive immunotherapy (PI) is being explored as a potent

48 Both active and passive immunotherapy protocols decrease insoluble amylo

49 a possible explanation of why adoptive (i.e. passive) immunotherapy protocols can sometimes actually

50 evaluate the potential efficacy of active or passive immunotherapy regimens as adjunctive treatments.

51 clinical trials are ongoing using active and passive immunotherapy targeting the amyloid-beta (Abeta)

52 ently, ~16% of participants in an anti-Abeta passive immunotherapy trial for mild-to-moderate Alzheim

53 Passive immunotherapy using fibril-reactive mAbs has bee

54 logical tau oligomers in aged Tg2576 mice by passive immunotherapy using tau oligomer-specific monocl

55 F4 can be used to identify AL candidates for passive immunotherapy using the chimeric form of the ant

56 ing through the B-cell and T-cell receptors; passive immunotherapies utilizing these receptors, such

57 Vectored passive immunotherapy with an anti-tau monoclonal antibo

58 The mainstay of prophylaxis has been passive immunotherapy with hepatitis B immune globulin (

59 Alzheimer's disease (AD) patients treated by passive immunotherapy with humanized anti-amyloid beta m

60 Despite the success of passive immunotherapy with monoclonal antibodies (mAbs),

61 Passive immunotherapy with monoclonal antibodies has imp

62 Passive immunotherapy with monoclonal antibodies is an i

63 fied as being farthest along in development; passive immunotherapy with monoclonal antibodies, postex

64 Among these strategies is passive immunotherapy with monoclonal antibody, alone or

65 Passive immunotherapy with RG-1 was protective in mice.

66 vide "proof of principle" for the ability of passive immunotherapy with rituximab to elicit an active

67 Although passive immunotherapy with these Abs are approved for tr

68 MAbs may provide the most effective form of passive immunotherapy, with the caveat that these may de